Discussing FDA clearance of Lyme ImmunoBlot

About The Event
The iDart Lyme IgG ImmunoBlot Kit is a stand-alone test for the detection of IgG antibodies against Borrelia-causing Lyme disease. The iDart ImmunoBlot Kit features 31 Lyme antigen bands, which are more antigen bands than any other Lyme immunoblot test on the market. Moreover, it is the only immunoblot that includes Osp A (P31) and Osp B (P34).

The inclusion of 31 antigens improves the sensitivity of the detection of Lyme-specific IgG antibodies, which in turn will improve the sensitivity of the diagnosis of Lyme disease in suspected patients without sacrificing specificity.

Dr. Joseph Burrascano will join Project Lyme to discuss the importance of this new test, its FDA clearance, as well as how it will impact the Lyme testing space and patients.

About the Presenter
Dr. Joseph Burrascano is a well-recognized specialist in the diagnosis and treatment of Lyme and associated complex infectious diseases and the chronic illnesses that accompany them. With over two decades of experience and research in this field, he has appeared in and on virtually every form of media, has advised the CDC and NIH, testified before the U.S. Senate, an armed services joint subcommittee, and at various governor’s councils. A founding member of ILADS, he currently is an active Board Member of the International Lyme and Associated Diseases Educational Foundation.

Disclosures
Dr. Joseph Burrascano is a paid consultant for IGeneX. Project Lyme does not directly endorse this product and gives this presentation as an educational tool for patients.

The information in this presentation has been validated by peer reviewed research. Full study here: https://pubmed.ncbi.nlm.nih.gov/30110...